We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verseon Corporation | LSE:VERS | London | Ordinary Share | COM USD0.001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.00 | 2.50 | 2.70 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVERS
RNS Number : 2900U
Verseon Corporation
28 March 2019
March 28, 2019
Verseon Corporation
("Verseon" or the "Company")
Further Update to Admission of Subscription Shares
FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that further to the announcement on March 22, 2019, the Directors now expect that Admission of the Subscription Shares, under a separate ISIN for Regulation S restricted stock, will take place on or around Tuesday, April 2, 2019.
About Verseon
Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.
Find Verseon on Twitter and LinkedIn.
- Ends -
For further information, please contact:
Verseon Corporation www.verseon.com Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000 Arden Partners (NOMAD and Joint Broker) Ruari McGirr / Ciaran Walsh / Alex +44 (0) 20 7614 Penney 5900 Cantor Fitzgerald Europe (Joint Broker) +44 (0) 20 7894 Phil Davies 7000
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) +44 (0) 20 7466 Henry Harrison-Topham / Jamie Hooper 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts +44 (0) 1737 821 Simon Vane Percy 890
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
FUREADDPAEANEEF
(END) Dow Jones Newswires
March 28, 2019 03:02 ET (07:02 GMT)
1 Year Verseon Chart |
1 Month Verseon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions